{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.5193","value":"23.018"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"OG000","title":"ACZ885"}],"paramType":"MEAN","populationDescription":"Intention to treat (ITT) population.","reportingStatus":"POSTED","timeFrame":"48 weeks after study start","title":"Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part III.","type":"SECONDARY","unitOfMeasure":"pg/mL"}